A novel Kv7 potassium channel opener, may offer a unique treatment option for patients with resistant focal onset seizures.

A new study published in JAMA Network Open highlights the significant environmental footprint of medical imaging contrast ...

First data reported from non-MTS and bilateral MTLE subjects demonstrate robust seizure reduction - LOW DOSE COHORT: 89% median reduction in disabling seizures for unilateral subjects with MTS at the ...

Brazil's Chamber of Deputies could allow former President Jair Bolsonaro a big reduction in 27-year prison sentence he is ...

Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant ...

Screening pregnant women at 36 weeks using a validated risk model and offering risk-stratified planned early-term birth ...

HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful ...

Two Appalachian states are bound by the same opioid crisis but are taking different paths forward. The Post traveled to West ...

London stocks nudged higher in early trade on Monday as investors eyed this week’s policy announcement from the US Federal ...

Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 ...

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1Holistic ...

Reducing risk: By switching from cigarettes to reduced-risk products like e-cigarettes, heated tobacco, or nicotine pouches, ...